In the SUSTAIN clinical trial program evaluating injectable semaglutide for type 2 diabetes, the 1 mg weekly dose reduced HbA1c by approximately 1.41.6% from baseline, while the SUSTAIN FORTE trial showed that the 2 mg dose provided additional glycemic benefits for patients needing intensification
Last reviewed: June 25, 2026 Last updated: June 25, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Non-Arteritic Anterior Ischemic Optic Neuropathy
What the Side Effects of GLP-1 Medications Mean for People With Eating Disorders The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and upset stomach
As semaglutide patents expire and generics enter the market, the cost gap between phentermine and semaglutide will narrow